Auranofin - Explore the Science & Experts | ideXlab


Scan Science and Technology

Contact Leading Edge Experts & Companies

Auranofin

The Experts below are selected from a list of 4098 Experts worldwide ranked by ideXlab platform

Auranofin – Free Register to Access Experts & Abstracts

Mukesh Kumar – One of the best experts on this subject based on the ideXlab platform.

  • the fda approved gold drug Auranofin inhibits novel coronavirus sars cov 2 replication and attenuates inflammation in human cells
    Virology, 2020
    Co-Authors: Hussin A Rothan, Shannon Stone, Janhavi P Natekar, Pratima Kumari, Komal Arora, Mukesh Kumar

    Abstract:

    SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, Auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with Auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that Auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of Auranofin for the management of SARS-COV-2 associated disease.

    Free Register to Access Article

  • the fda approved gold drug Auranofin inhibits novel coronavirus sars cov 2 replication and attenuates inflammation in human cells
    bioRxiv, 2020
    Co-Authors: Hussin A Rothan, Shannon Stone, Janhavi P Natekar, Pratima Kumari, Komal Arora, Mukesh Kumar

    Abstract:

    SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved gold drug, Auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with Auranofin resulted in a 95% reduction in the viral RNA at 48 hours after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that Auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its anti-viral, anti-inflammatory and anti-ROS properties. Auranofin has a well-known toxicity profile and is considered safe for human use.

    Free Register to Access Article

Hang Xiang – One of the best experts on this subject based on the ideXlab platform.

  • a high throughput drug screen identifies Auranofin as a potential sensitizer of cisplatin in small cell lung cancer
    Investigational New Drugs, 2019
    Co-Authors: Xiaoli Liu, Hang Xiang, Wei Wang, Yanping Yin

    Abstract:

    Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we developed a high-throughput drug screen strategy to identify new drugs that can enhance the sensitivity of chemo-drug cisplatin in SCLC. This screen identified Auranofin, a US Food and Drug Administration (FDA)-approved drug used therapeutically for rheumatoid arthritis, as a sensitizer of cisplatin. Further study validated that Auranofin synergistically enhanced the anti-tumor activity of cisplatin in chemo-resistant SCLC cells, which was accompanied by the enhanced induction of cell cycle arrest and apoptosis. The synergistic action of Auranofin and cisplatin was through ROS overproduction, thereby leading to mitochondrial dysfunction and DNA damage. Furthermore, in vivo study demonstrated that the combination treatment of Auranofin and cisplatin dramatically inhibited tumor growth in SCLC. Therefore, our study provides a rational basis for further clinical study to test whether Auranofin could enhance the sensitivity of cisplatin-based therapy in SCLC patients.

    Free Register to Access Article

Xiaoli Liu – One of the best experts on this subject based on the ideXlab platform.

  • a high throughput drug screen identifies Auranofin as a potential sensitizer of cisplatin in small cell lung cancer
    Investigational New Drugs, 2019
    Co-Authors: Xiaoli Liu, Hang Xiang, Wei Wang, Yanping Yin

    Abstract:

    Small cell lung cancer (SCLC) is a highly lethal malignancy with the 5-year survival rate of less than 7%. Chemotherapy-resistance is a major challenge for SCLC treatment in clinic. In the study, we developed a high-throughput drug screen strategy to identify new drugs that can enhance the sensitivity of chemo-drug cisplatin in SCLC. This screen identified Auranofin, a US Food and Drug Administration (FDA)-approved drug used therapeutically for rheumatoid arthritis, as a sensitizer of cisplatin. Further study validated that Auranofin synergistically enhanced the anti-tumor activity of cisplatin in chemo-resistant SCLC cells, which was accompanied by the enhanced induction of cell cycle arrest and apoptosis. The synergistic action of Auranofin and cisplatin was through ROS overproduction, thereby leading to mitochondrial dysfunction and DNA damage. Furthermore, in vivo study demonstrated that the combination treatment of Auranofin and cisplatin dramatically inhibited tumor growth in SCLC. Therefore, our study provides a rational basis for further clinical study to test whether Auranofin could enhance the sensitivity of cisplatin-based therapy in SCLC patients.

    Free Register to Access Article